Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington’s Disease: A Possible Biomarker of Disease Progression?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Huntington’s disease (HD) is an autosomal-dominant inherited neurodegenerative disorder. Genetic analysis of abnormal CAG expansion in the IT15 gene allows disease confirmation even in the preclinical stage. However, because there is no treatment to cure or delay the progression of this disease, monitoring of biological markers that predict progression is warranted. Methods FDG-PET was applied to 13 patients with genetically confirmed HD in the early stage of the disease. We recorded the initial and follow-up statuses of patients using the Independence Scale (IS) of the Unified Huntington’s Disease Rating Scale. The progression rate (PR) was calculated as the annual change in the IS. The patients were divided into two groups with faster and slower progression, using the median value of the PR as the cut-off. FDG-PET data were analyzed using regions of interest, and compared among the two patient groups and 11 age- and sexmatched controls. Results The mean CAG repeat size in patients was 44.7. The CAG repeat length was inversely correlated with the age at onset as reported previously, but was not correlated with the clinical PR. Compared with normal controls, hypometabolism was observed even at very early stages of the disease in the bilateral frontal, temporal, and parietal cortices on FDG-PET. The decreases in metabolism in the bilateral frontal, parietal, and right temporal cortices were much greater in the faster-progression group than in the slower-progression group. Conclusions A decrease in cortical glucose metabolism is suggested as a predictor for identifying a more rapid form of progression in patients with early-stage HD.
Abstract
Background and Purpose Huntington’s disease (HD) is an autosomal-dominant inherited neurodegenerative disorder. Genetic analysis of abnormal CAG expansion in the IT15 gene allows disease confirmation even in the preclinical stage. However, because there is no treatment to cure or delay the progression of this disease, monitoring of biological markers that predict progression is warranted. Methods FDG-PET was applied to 13 patients with genetically confirmed HD in the early stage of the disease. We recorded the initial and follow-up statuses of patients using the Independence Scale (IS) of the Unified Huntington’s Disease Rating Scale. The progression rate (PR) was calculated as the annual change in the IS. The patients were divided into two groups with faster and slower progression, using the median value of the PR as the cut-off. FDG-PET data were analyzed using regions of interest, and compared among the two patient groups and 11 age- and sexmatched controls. Results The mean CAG repeat size in patients was 44.7. The CAG repeat length was inversely correlated with the age at onset as reported previously, but was not correlated with the clinical PR. Compared with normal controls, hypometabolism was observed even at very early stages of the disease in the bilateral frontal, temporal, and parietal cortices on FDG-PET. The decreases in metabolism in the bilateral frontal, parietal, and right temporal cortices were much greater in the faster-progression group than in the slower-progression group. Conclusions A decrease in cortical glucose metabolism is suggested as a predictor for identifying a more rapid form of progression in patients with early-stage HD.
참고문헌 (21)
- The American College of Medical Genetics, "American Society of Human Genetics Huntington Disease Genetic Testing Working Group", ACMG, The American Journal of Human Genetics, pp.1998, 62[DOI]
- Kremer B, "A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats", The New England Journal of Medicine, 330, pp.1401~1406 (1994)
- Hersch S, "Neuropathology and pathophysiology of Huntington’s disease" (2004), McGraw-Hill
- Hayden MR, "The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington’s disease", Neurology, 37, pp.1441~1447 (1987)
- Mazziotta JC, "Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease", The New England Journal of Medicine, 316, pp.357~362 (1987)
- Grafton ST, "A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington’s disease", Annals of Neurology, 28, pp.614~621 (1990)
- Antonini A, "Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease", Brain, 119, pp.2085~2095 (1996)
- Rosas HD, "Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity", Brain, 131, pp.1057~1068 (2008)
- Rosas HD, "Regional and progressive thinning of the cortical ribbon in Huntington’s disease", Neurology, 58, pp.695~701 (2002)
- Martin WR, "Cortical glucose metabolism in Huntington’s disease", Neurology, 42, pp.223~229 (1992)
- Kuwert T, "Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease", Brain, 113, pp.1405~1423 (1990)
- Ashizawa T, "CAG repeat size and clinical presentation in Huntington’s disease", Neurology, 44, pp.1137~1143 (1994)
- Kieburtz K, "Trinucleotide repeat length and progression of illness in Huntington’s disease", Journal of Medical Genetics, 31, pp.872~874 (1994)
- Esmaeilzadeh M, "Seeking brain biomarkers for preventive therapy in Huntington disease", CNS Neuroscience & Therapeutics, 17, pp.368~386 (2011)
- Squitieri F, "Molecular medicine: predicting and preventing Huntington’s disease", Neurological Sciences, 29, pp.205~207 (2008)
- Aylward EH, "Basal ganglia volume and proximity to onset in presymptomatic Huntington disease", Archives of neurology, 53, pp.1293~1296 (1996)
- Aylward EH, "Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons", Neurology, 44, pp.823~828 (1994)
- raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length, "Annals of Neurology", 1998, 253~255
- Thieben MJ, "The distribution of structural neuropathology in pre-clinical Huntington’s disease", Brain, 125, pp.1815~1828 (2002)
- Rosas HD, "Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis", Neurology, 60, pp.1615~1620 (2003)
- Ciarmiello A, "Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease", Journal of Nuclear Medicine, 47, pp.215~222 (2006)